Login to Your Account

Plexxikon, Wyeth PPAR Deal: Up To $372M In Diabetes Bid

By Randall Osborne

Monday, November 1, 2004
If there's anxiety lingering after the FDA's summer ruling about potential cancer toxicity with peroxisome proliferator-activated receptors (PPARs), you wouldn't know it from Wyeth - which entered a potential $372 million deal with Plexxikon Inc. to develop treatments for diabetes and metabolic disorders. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription